Document is current

Article History

Received: 10 June 2024

Accepted: 20 September 2024

First Online: 19 November 2024

Acknowledgements

: We are grateful to study volunteers for their participation. We acknowledge support by L. Cavalli, E. Leu, C. Gisler (UDEM, Inselspital, Bern, Switzerland), M. Vajner and S. Rocha (Division of Paediatric Endocrinology and Diabetology, University Children's Hospital, Zurich, Switzerland) who contributed to participant care, logistical and administrative management of the study.An abstract of study results was presented in March 2024 at the Advanced Technologies & Treatments for Diabetes conference in Florence, Italy and at the Swiss Society of Paediatrics annual meeting in June 2024 in Lucerne, Switzerland.

: De-identified subject level dataset will be made available on a case-by-case basis on reasonable request to the corresponding author for research purposes 6 months after publication.

: Open access funding provided by University of Bern. The study was supported by the Swiss Diabetes Foundation and by a YTCR grant from the Bangerter-Rhyner Foundation and the Swiss Academy of Medical Sciences. Dexcom and Ypsomed provided product support.

: CIL received a travel grant from the Swiss Society of Endocrinology and Diabetology to present the present work at the Advanced Technologies & Treatments for Diabetes conference in Florence, Italy (Abstract no. 181). KB-K has received research funding from Dexcom, Embecta, Novo Nordisk and Eli Lilly, as well as honoraria from Tandem, Dexcom, Sanofi and Roche. MEW reports patents related to closed-loop (US9402953B2, US9579456B2), and being a consultant at CamDiab. RH reports having received speaker honoraria from Eli Lilly, Dexcom and Novo Nordisk, receiving license fees from BBraun, patents related to closed-loop, and being a director at CamDiab. LB reports having received speaker and advisory board honoraria from Eli Lilly, Dexcom, Novo Nordisk, Ypsomed, Roche, Sanofi and Oviva.

: CIL, CP, FN, NS, KB-K, LK, DH, DK and LB were involved in the conception, design and conduct of the study and the analysis and interpretation of the results. CIL, CP, FN, NS, LK, KB-K, TZ, DH, DK and LB were involved in the conception of the study and data acquisition. DH, CTN, CIL, KB-K, MEW, RH and LB were involved in the analysis and interpretation of the results. CIL, DH and LB wrote the first draft of the manuscript, and all authors edited, reviewed and approved the final version of the manuscript. CIL, DH, DK and LB are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.